Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study

References

• Cabinet Public Affairs Office, Cabinet Secretariat. COVID-19 vaccines; [accessed 2023 July 20]. https://japan.kantei.go.jp/ongoingtopics/vaccine.html.
   Google Scholar
• Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, Buckley BS, Probyn K, Villanueva G, Henschke N, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;12:CD015477. doi:10.1002/14651858.CD015477.
   PubMedGoogle Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide Mass vaccination setting. N Engl J Med. 2021;384(15):1412–6. doi:10.1056/NEJMoa2101765.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, et al. Safety of the BNT162b2 mRNA COVID-19 Vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–90. doi:10.1056/NEJMoa2110475.
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390. doi:10.1001/jama.2021.15072.
   PubMed Web of Science ®Google Scholar
• Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, Sørensen HT, Andersen M, Wohlfahrt J, Gislason G, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021;375:e068665. doi:10.1136/bmj-2021-068665.
   PubMedGoogle Scholar
• CDC. Selected adverse events reported after COVID-19 vaccination; 2023 [accessed 2023 July 4]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html.
   Google Scholar
• Rosenblum HG, Gee J, Liu R, Marquez PL, Zhang B, Strid P, Abara WE, McNeil MM, Myers TR, Hause AM, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the vaccine adverse event reporting system and v-safe. Lancet Infect Dis. 2022;22(6):802–12. doi:10.1016/S1473-3099(22)00054-8.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. Summary of cases reported as deaths following COVID-19 vaccination (spikevax) [In Japanese]; 2023 [accessed 2023 July 4]. https://www.mhlw.go.jp/content/10601000/001092258.pdf.
   Google Scholar
• Ministry of Health, Labour and Welfare. Summary of cases reported as deaths following COVID-19 vaccination (comirnaty) [In Japanese]; 2023 [accessed 2023 July 4]. https://www.mhlw.go.jp/content/10601000/001092112.pdf.
   Google Scholar
• Xu S, Huang R, Sy LS, Glenn SC, Ryan DS, Morrissette K, Shay DK, Vazquez-Benitez G, Glanz JM, Klein NP, et al. COVID-19 vaccination and non–COVID-19 mortality risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1520–4. doi:10.15585/mmwr.mm7043e2.
   PubMed Web of Science ®Google Scholar
• Xu S, Huang R, Sy LS, Hong V, Glenn SC, Ryan DS, Morrissette K, Vazquez-Benitez G, Glanz JM, Klein NP, et al. A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. Vaccine. 2023;41(3):844–54. doi:10.1016/j.vaccine.2022.12.036.
   PubMed Web of Science ®Google Scholar
• Bardenheier BH, Gravenstein S, Blackman C, Gutman R, Sarkar IN, Feifer RA, White EM, McConeghy K, Nanda A, Mor V. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine. 2021;39(29):3844–51. doi:10.1016/j.vaccine.2021.05.088.
   PubMed Web of Science ®Google Scholar
• Stivanello E, Beghelli C, Cardoni F, Giansante C, Marzaroli P, Musti MA, Perlangeli V, Todeschini R, Pandolfi P. Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study. Vaccine. 2022;40(39):5709–15. doi:10.1016/j.vaccine.2022.08.039.
   PubMed Web of Science ®Google Scholar
• Wong CKH, Lau KTK, Xiong X, Au ICH, Lai FTT, Wan EYF, Chui CSL, Li X, Chan EWY, Gao L, et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: a retrospective study. PLOS Med. 2022;19(6):e1004018. doi:10.1371/journal.pmed.1004018.
   PubMed Web of Science ®Google Scholar
• Lopez-Doriga Ruiz P, Gunnes N, Michael Gran J, Karlstad Ø, Selmer R, Dahl J, Bøås H, Aubrey White R, Christine Hofman A, Hessevik Paulsen T, et al. Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway. Vaccine. 2023;41(2):323–32. doi:10.1016/j.vaccine.2022.10.085.
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Iwagami M, Ono S, Michihata N, Uemura K, Yasunaga H. A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan. Vaccine. 2022;40(52):7622–30. doi:10.1016/j.vaccine.2022.10.088.
   PubMed Web of Science ®Google Scholar
• Nafilyan V, Bermingham CR, Ward IL, Morgan J, Zaccardi F, Khunti K, Stanborough J, Banerjee A, Doidge JC. Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England. Nat Commun. 2023;14(1):1541. doi:10.1038/s41467-023-36494-0.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Pearce N. Case-control studies: basic concepts. Int J Epidemiol. 2012;41(5):1480–9. doi:10.1093/ije/dys147.
   PubMed Web of Science ®Google Scholar
• Fukuda H, Maeda M, Murata F. Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: the VENUS study. Vaccine. 2023;41(23):3556–63. doi:10.1016/j.vaccine.2023.03.059.
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9. doi:10.1097/01.mlr.0000182534.19832.83.
   PubMed Web of Science ®Google Scholar
• Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC Infect Dis. 2015;15(1):429. doi:10.1186/s12879-015-1154-y.
   PubMedGoogle Scholar
• Ministry of Health, Labour and Welfare. Preliminary reports of third survey of SARS-CoV-2 seroprevalence in blood donors in Japan [In Japanese]; 2023 [accessed 2023 July 20]. https://www.mhlw.go.jp/content/10900000/001108939.pdf.
   Google Scholar